Floatz logo

Humax-Cd20

Monoclonal Paraproteinemia Disease

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Monoclonal Paraproteinemia Disease cohort.

Asset / SponsorPhaseRating
Lenalidomide
Hellenic Society of Hematology
Phase 3BB
Pomalidomide
Hellenic Society of Hematology
Phase 2B
Dexasone
Hellenic Society of Hematology
Phase 2B
Ranitidine
Hellenic Society of Hematology
Phase 2CCC
Isatuximab
Hellenic Society of Hematology
Phase 2CCC

View all 14 →

Same molecule, other indications

Humax-Cd20 is also rated in:

B-cell chronic lymphocytic leukemiaDormant
BBB
Indicative · Phase 4
78 / 100
View asset →
relapsing-remitting multiple sclerosisActive
BBB
Indicative · Phase 4
74 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative · Phase 3
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →